Hydroxychloroquine can actually reduce EAU!

Autoimmune uveitis (AU) is a chronic inflammatory disease affecting eye tissues, including the retina and retinal vessels, and is the fifth most common cause
of blindness worldwide.

Experimental autoimmune uveitis (EAU) is a widely used T-cell-mediated AU model that is immunoinduced by using the photoreceptor retinoid-binding protein 1-20 (IRBP 1-20) in an
adjuvant environment.

Chloroquine (CQ) and its hydroxy-group analogue, hydroxychloroquine (HCQ), are low-cost antimalarial drugs with few side effects and have been used for half a century
.

Hydroxychloroquine (HCQ) reduces inflammation of the retina in experimental autoimmune uveitis (EAU):

Methods: C57BL/6J mice were immunized with retinoid-binding protein 1-20 (IRBP 1-20) to induce EAU, and then treated
with vector or HCQ (100 mg/kg/day).

Hydroxychloroquine (HCQ) reduces inflammation caused by inflammation of retinal vascular endothelial cells (RVEC) dysfunction:

Results: HCQ therapy protects mice from uveitis, which can be demonstrated
by a decrease in the expression of inflammatory factors, chemokines, and adhesion molecules in the retina.

Hydroxychloroquine (HCQ) regulates TNF-α-stimulated endothelial dysfunction by the LOX-1/NF-κB axis:

In summary, the therapeutic effect of HCQ on uveitis is demonstrated
.

References: Hu Y, Li Z, Chen G, Li Z, Huang J, Huang H, Xie Y, Chen Q, Zhu W, Wang M, Chen J, Su W, Chen X, Liang D.